Modular Platform for Combinatorial Epigenome Manipulation
Modular Platform for Combinatorial Epigenome Manipulation
批准号:
10592628
负责人:
Mark D ADAMS
金额:
$73.47万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-01-01 至 2023-12-31
关键词:
AddressAdoptionAffectAmino Acid SequenceBiologicalBiological AssayBiological ModelsBiological ProcessCell LineCell modelCell physiologyCellsChIP-seqClustered Regularly Interspaced Short Palindromic RepeatsCommunitiesCustomDNADepositionDevelopmentDevelopmental ProcessDiseaseEcosystemElementsEngineeringEnhancersEnzymesEpigenetic ProcessEtiologyGene ExpressionGene Expression RegulationGenesGenomicsGoalsGuide RNAHealthHistonesIn SituIndividualKnock-outLibrariesLinkMapsMethodologyModificationMolecularOpen Reading FramesPathway interactionsPhenotypePhysiologyPlasmidsPlayProteinsProtocols documentationPublishingRNA libraryReagentRegistriesRegulator GenesRegulatory ElementReporterResearch PersonnelResourcesScientistShapesSiteSpecificityStretchingSystemTechniquesTechnologyTherapeutic InterventionTransgenesTranslatingValidationbasecase-by-case basiscell typecombinatorialcomputational pipelinesdesigndevelopmental diseaseepigenetic regulationepigenomeepigenome editingepigenomicsexperimental studyfunctional genomicsgene regulatory networkgenome-widegenome-wide analysisgenomic locushistone modificationhuman embryonic stem cellin vivoinduced pluripotent stem cellinnovationinsightinterestnext generationnext generation sequencingnovelpersonalized medicineprecision medicineprogramspromoterrepositoryself-renewalside effecttooltranscriptome sequencing
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Epigenetic modifications of histone and DNA control gene expression and critically shape phenotypes and cell
states. These modifications are tightly controlled by interactions with a constellation of trans-acting regulatory
factors, and are dysregulated in a plethora of diseases. Next-generation sequencing (NGS) technologies have
allowed genome-wide profiling of these modifications in diverse cell types, normal and disease conditions as
well as across individuals. However, these strategies have yielded mostly associative and/or correlative insight
into relationships between epigenetic state, gene expression and phenotype with limited power to establish the
causality of individual epigenetic modifications that is fundamental to understanding normal physiology and
diseases. Existing techniques to investigate phenotypic consequences of epigenetic gene regulation
irreversibly delete stretches of genomic sequence that can have multiple functions, or perturb protein factors
that control thousands of genes, confounding accurate conclusion. A scalable toolbox allowing in situ and in
vivo combinatorial modifications of epigenetic states would offer unprecedented opportunities for both
mechanistic studies and unbiased discovery of novel functional elements at the genomic scale. This project will
respond to this need by developing an expandable molecular toolkit to precisely and reversibly manipulate
defined epigenetic modifications (e.g., H3K27ac) at defined genomic addresses based on our innovative
CRISPR/Casilio platform. There are three Specific Aims in this project. Aim 1 is focused on the development of
a comprehensive set of epigenetic editing modules with which Casilio can achieve multiplexed and
combinatorial edits, whereby different epigenetic modifications can be elicited simultaneously at distinct
genomic loci while multiple modifications can also be induced in each locus. Aim 2 will deliver Casilio-enabled
cell lines with which scientists can achieve epigenome editing with unprecedented ease by delivering short
RNA guides. Aim 3 will center on the development of genome-wide guide libraries targeting genomic
regulatory elements such as enhancers and insulators with which scientists can perform reverse epigenetic
screens to discover novel elements and epigenetic modifications causative to phenotype. This toolkit, once
developed, will transform the ways we study epigenetics by providing a fine and scalable technique to directly
edit epigenetic states at defined targets, to investigate the underlying causes of gene regulatory changes
observed in biological processes and diseases. To truly benefit the field of functional genomics, we will share
our methodology and reagents at every stage of platform development with the scientific community. Through
the establishment of standards and a module registry as well as reagent sharing via an open repository, we
hope to create a sustainable ecosystem of Casilio module users and developers to apply and expand the
Casilio toolbox for epigenetic editing. Due to the programmability and precision, epigenetic editing enabled by
Casilio may provide new means and tools for powering personalized and precision medicine.
期刊论文(3)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1089/crispr.2022.0042
发表时间:
2022-08
期刊:
The CRISPR journal
影响因子:
--
作者:
[]
通讯作者:
DOI:
10.1093/nar/gkad547
发表时间:
2023-08-11
期刊:
NUCLEIC ACIDS RESEARCH
影响因子:
14.9
作者:
[Liu, Zukai, Jillette, Nathaniel, Robson, Paul, Cheng, Albert Wu]
通讯作者:
Cheng, Albert Wu
Genome Technologies Coordinating Center
-
批准号:10571905
-
项目类别:
-
资助金额:$149.81万
-
财政年份:2021
-
负责人:Mark D ADAMS
-
依托单位:
Genome Technologies Coordinating Center
-
批准号:10213304
-
项目类别:
-
资助金额:$63.33万
-
财政年份:2021
-
负责人:Mark D ADAMS
-
依托单位:
Genome Technologies Coordinating Center
-
批准号:10408042
-
项目类别:
-
资助金额:$149.81万
-
财政年份:2021
-
负责人:Mark D ADAMS
-
依托单位:
Impact of Mitochondrial Genome Variation on extreme Prostate Cancer Disparities
-
批准号:8519389
-
项目类别:
-
资助金额:$17.79万
-
财政年份:2012
-
负责人:Mark D ADAMS
-
依托单位:
A Digital Microfluidic Systems for Gene Synthesis, Sequencing and Recovery
-
批准号:8532939
-
项目类别:
-
资助金额:$22.02万
-
财政年份:2012
-
负责人:Mark D ADAMS
-
依托单位:
A Digital Microfluidic Systems for Gene Synthesis, Sequencing and Recovery
-
批准号:8352845
-
项目类别:
-
资助金额:$24.88万
-
财政年份:2012
-
负责人:Mark D ADAMS
-
依托单位:
Evolution of multidrug resistance in Acinetobacter baumannii
-
批准号:8535790
-
项目类别:
-
资助金额:$31.01万
-
财政年份:2011
-
负责人:Mark D ADAMS
-
依托单位:
Evolution of multidrug resistance in Acinetobacter baumannii
-
批准号:8325561
-
项目类别:
-
资助金额:$32.14万
-
财政年份:2011
-
负责人:Mark D ADAMS
-
依托单位:
Genomics
-
批准号:8555234
-
项目类别:
-
资助金额:$17.26万
-
财政年份:2011
-
负责人:Mark D ADAMS
-
依托单位:
Evolution of multidrug resistance in Acinetobacter baumannii
-
批准号:8726429
-
项目类别:
-
资助金额:$32.14万
-
财政年份:2011
-
负责人:Mark D ADAMS
-
依托单位:
Evolution of multidrug resistance in Acinetobacter baumannii
-
批准号:8107146
-
项目类别:
-
资助金额:$32.14万
-
财政年份:2011
-
负责人:Mark D ADAMS
-
依托单位:
AFRICAN TRYPANOSOME GENOME SEQUENCING
-
批准号:2637350
-
项目类别:
-
资助金额:$69.18万
-
财政年份:1998
-
负责人:Mark D ADAMS
-
依托单位:
SEQUENCING OF HUMAN CHROMOSOME 16P
-
批准号:2805292
-
项目类别:
-
资助金额:$0.05万
-
财政年份:1996
-
负责人:Mark D ADAMS
-
依托单位:
SEQUENCING OF HUMAN CHROMOSOME 16P
-
批准号:2392524
-
项目类别:
-
资助金额:$727.44万
-
财政年份:1996
-
负责人:Mark D ADAMS
-
依托单位:
SEQUENCING OF HUMAN CHROMOSOME 16P
-
批准号:2209782
-
项目类别:
-
资助金额:$363.04万
-
财政年份:1996
-
负责人:Mark D ADAMS
-
依托单位:
SEQUENCING OF HUMAN CHROMOSOME 16P
-
批准号:2758513
-
项目类别:
-
资助金额:$144.43万
-
财政年份:1996
-
负责人:Mark D ADAMS
-
依托单位:
Genomics
-
批准号:8567138
-
项目类别:
-
资助金额:$16.07万
-
财政年份:--
-
负责人:Mark D ADAMS
-
依托单位:
Genomics
-
批准号:8711350
-
项目类别:
-
资助金额:$16.32万
-
财政年份:--
-
负责人:Mark D ADAMS
-
依托单位:
Technology Core
-
批准号:8831598
-
项目类别:
-
资助金额:$123.28万
-
财政年份:--
-
负责人:Mark D ADAMS
-
依托单位:
Technology Core
-
批准号:8711785
-
项目类别:
-
资助金额:$140.74万
-
财政年份:--
-
负责人:Mark D ADAMS
-
依托单位:
海外基金